Bausch Health Patent-Cliff Exposure & CMS Drug Spending Portfolio

Bausch Health (Bridgewater, NJ): 114 reconciled FDA prescription therapies (72.6% 2025 to 2030 cliff risk), $3.52B 2024 CMS Part D & Medicaid spend, and 231 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterBridgewater, NJ
Reconciled FDA Portfolio Therapies114
2025 to 2030 Patent-Cliff Revenue Exposure72.6%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$3.52B
2024 Medicare Part D Spend$2.69B
2024 Medicaid Spend$828.0M
California HCAI SB 17 Filings231 WAC filings (max 85.5% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.